EQUITY RESEARCH – RESULTS FLASH

# **BANGKOK DUSIT MEDICAL SERVICES**

THAILAND / HEALTH CARE SERVICES

# 2Q24 results at first glance

# 2Q24 core profit grew by 9% y-y to THB3.3b, in line with our estimate

### Highlights

- BDMS reported a core profit of THB3.3b in 2Q24 (+9% y-y, -18% qq), in line with our estimate.
- Hospital revenue grew 7% y-y to THB26.1b. International patient revenue grew 11% y-y, driven by patient revenue from Qatar (+66% y-y), the UAE (+32% y-y) and the USA (+31% y-y). Meanwhile, Thai patient revenue grew 5% y-y.
- COGS increased by 8% y-y and SG&A increased by 6% y-y in the quarter. As a result, the EBITDA margin slightly declined to 22.1% (vs 22.6% in 2Q23) due to a lower occupancy rate and the economies of scale.
- 1H24 core profit grew by 13% y-y to THB7.4b and accounted for 45% of our 2024 core profit forecast of THB16.4b.

#### **Outlook and recommendation**

- 1H24 revenue grew by 9% y-y. We believe that revenue growth in 2H24 should accelerate to 11-12% y-y from the high healthcare season in 3Q24. This would lead the 2024 revenue to hit management's target of 10-12%.
- BDMS is trading at an attractive valuation of 27x 2024E P/E, lower than its five-year average of 31x. The share price catalyst is a potential new earnings high in 3Q24.



# FSSIA ESG rating \*\*\*\* BDMS TB BUY UNCHANGED

TARGET PRICE	THB35.00
CLOSE	THB27.75
UP/DOWNSIDE	+26.1%
TP vs CONSENSUS	+0.1%

# **KEY STOCK DATA**

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	102,110	112,311	121,304	131,022
Net profit	14,375	16,413	17,928	19,652
EPS (THB)	0.90	1.03	1.13	1.24
vs Consensus (%)	-	2.5	3.6	3.2
EBITDA	24,740	27,717	30,179	32,859
Recurring net profit	14,375	16,413	17,928	19,652
Core EPS (THB)	0.90	1.03	1.13	1.24
EPS growth (%)	14.0	14.2	9.2	9.6
Core P/E (x)	30.7	26.9	24.6	22.4
Dividend yield (%)	2.3	2.5	2.6	2.8
EV/EBITDA (x)	18.3	16.3	14.8	13.4
Price/book (x)	4.6	4.4	4.1	3.9
Net debt/Equity (%)	8.8	6.2	1.1	(3.9)
ROE (%)	15.5	16.8	17.3	17.8



Share price performance	1 Month	3 Month	12 Month			
Absolute (%)	6.7	(5.1)	(3.5)			
Relative to country (%)	9.5	0.3	14.2			
Mkt cap (USD m)			12,541			
3m avg. daily turnover (USD m)	3m avg. daily turnover (USD m) 2					
Free float (%)			70			
Major shareholder		Thai N\	/DR (13%)			
12m high/low (THB)		3	0.00/25.00			
Issued shares (m)			15,892.00			

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523

teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

### Exhibit 1: BDMS - 2Q24 results summary

	2Q23	3Q23	4Q23	1Q24	2Q24	C <u>ha</u>	nge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Sales	24,372	26,699	26,726	26,930	26,058	(3)	7	102,110	112,311	10
- Hospital revenue	23,141	25,473	25,379	25,526	24,694	(3)	7	97,077	106,875	10
- Other revenue	1,232	1,227	1,346	1,404	1,364	(3)	11	5,034	5,436	8
COGS (incl depreciation)	(15,432)	(16,469)	(16,389)	(16,736)	(16,664)	(0)	8	(63,412)	(69,333)	9
Gross profit	8,940	10,230	10,337	10,194	9,394	(8)	5	38,698	42,979	11
SG&A	(4,876)	(5,106)	(5,191)	(4,893)	(5,146)	5	6	(19,806)	(21,504)	9
Operating profit <sup>1)</sup>	4,064	5,124	5,146	5,301	4,248	(20)	5	18,892	21,475	14
Net other income	5	7	19	9	23	155	324	43	48	10
Interest income	48	48	52	48	47	(1)	(0)	173	110	(37)
Interest expense	(134)	(122)	(126)	(113)	(111)	(2)	(18)	(547)	(501)	(8)
Pretax profit	3,983	5,057	5,091	5,246	4,208	(20)	6	18,563	21,131	14
Income Tax	(812)	(1,025)	(1,038)	(1,042)	(756)	(27)	(7)	(3,755)	(4,226)	13
Associates	13	21	22	13	14	9	11	89	98	10
Minority interest	(120)	(163)	(123)	(143)	(131)	(8)	9	(522)	(590)	13
Core profit	3,063	3,890	3,952	4,074	3,335	(18)	9	14,375	16,413	14
Extraordinaries, GW & FX	.,	-,	- ,	,-		( )		0	0	
Reported net profit	3,063	3,890	3,952	4,074	3,335	(18)	9	14,375	16,413	14
	-,	-,	-,	.,	-,	()		.,	,	
Outstanding shares (m)	15,892	15,892	15,892	15,892	15,892	0	0	15,892	15,892	0
	0.40	0.04	0.05	0.00	0.24	(4.9)	0	0.00	4.02	
Core EPS (THB)	0.19	0.24	0.25	0.26	0.21	(18)	9	0.90	1.03	14
EPS (THB)	0.19	0.24	0.25	0.26	0.21	(18)	9	0.90	1.03	14
COGS excl depreciation	13,986	14,999	14,886	15,259	15,161	(1)	8	57,564	63,090	10
Depreciation	1,446	1,470	1,503	1,477	1,503	2	4	5,848	6,243	7
EBITDA <sup>2)</sup>	5,510	6,594	6,649	6,778	5,751	(15)	4	24,740	27,717	12
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	37	38	39	38	36	(2)	(1)	38	38	0
SG&A/Revenue	20	19	19	18	20	2	(0)	19	19	(0)
EBITDA margin	22.6	25	25	25	22.1	(3)	(1)	24	25	0
Net profit margin	13	15	15	15	13	(2)	0	14	15	1
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	10	14	10	13	12					
OPD volume growth y-y	0	0	5	12						
OPD revenue per head growth y-y	10	14	5	1						
IPD revenue growth y-y	10	9	15	8	9					
IPD volume growth y-y	60	9 20	13	17	J					
IPD revenue per head growth y-y	(31)	(9)	(2)	(7)						
n b revenue per neau growin y-y	(31)	(9)	(2)	(7)						
Thai revenue growth y-y	7	9	10	10	5					
International revenue growth y-y	22	19	18	12	11					

Note: 1) Gross profit calculated by revenue – COGS including depreciation; 2) EBITDA calculated by operating profit + operating income – depreciation Sources : BDMS; FSSIA estimates



# **Financial Statements**

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	20268
Revenue	92,968	102,110	112,311	121,304	131,022
Cost of goods sold	(58,329)	(63,412)	(69,333)	(74,787)	(80,610
Gross profit	34,638	38,698	42,979	46,518	50,413
Other operating income	-	-	-	-	
Operating costs	(17,655)	(19,806)	(21,504)	(23,104)	(24,824
Operating EBITDA	22,933	24,740	27,717	30,179	32,859
Depreciation	(5,950)	(5,848)	(6,243)	(6,766)	(7,271
Goodwill amortisation	-	-	-	-	
Operating EBIT	16,984	18,892	21,475	23,413	25,588
Net financing costs	(552)	(373)	(391)	(358)	(288
Associates	42	89	98	108	119
Recurring non-operating income	50	133	146	161	17
Non-recurring items	0	0	0	0	(
Profit before tax	16,481	18,652	21,230	23,216	25,477
Tax	(3,227)	(3,755)	(4,226)	(4,622)	(5,072
Profit after tax	13,254	14,897	17,003	18,595	20,400
Minority interests	(648)	(522)	(590)	(667)	(753
Preferred dividends	-	-	-	-	
Other items	-	-	-	-	
Reported net profit	12,606	14,375	16,413	17,928	19,652
Non-recurring items & goodwill (net)	0	0	0	0	(
Recurring net profit	12,606	14,375	16,413	17,928	19,652
Per share (THB)					
Recurring EPS *	0.79	0.90	1.03	1.13	1.24
Reported EPS	0.79	0.90	1.03	1.13	1.24
DPS	0.50	0.65	0.70	0.72	0.79
Diluted shares (used to calculate per share data)	15,892	15,892	15,892	15,892	15,892
Growth					
Revenue (%)	23.1	9.8	10.0	8.0	8.0
Operating EBITDA (%)	32.2	7.9	12.0	8.9	8.9
Operating EBIT (%)	54.1	11.2	13.7	9.0	9.3
Recurring EPS (%)	63.0	14.0	14.2	9.2	9.6
Reported EPS (%)	58.8	14.0	14.2	9.2	9.6
Operating performance	00.0	1110		0.2	0.0
Gross margin inc. depreciation (%)	37.3	37.9	38.3	38.3	38.5
Gross margin exc. depreciation (%)	43.7	43.6	43.8	43.9	44.0
Operating EBITDA margin (%)	43.7 24.7	43.8 24.2	43.8 24.7	43.9 24.9	44.0 25.1
Operating EBITDA margin (%) Operating EBIT margin (%)	24.7 18.3	24.2 18.5	24.7 19.1	24.9 19.3	25. 19.5
	13.6	14.1	14.6	19.3	19.0
Net margin (%)					
Effective tax rate (%)	19.6 63.0	20.2	20.0	20.0	20.0 63.9
Dividend payout on recurring profit (%)	63.0 20.8	71.9	67.8	64.1	
Interest cover (X)	30.8	51.0	55.3	65.9	89.5
Inventory days	14.7	14.7	14.7	14.8	14.8
Debtor days	38.5	39.4	37.6	34.8	32.2
Creditor days	39.1	41.5	41.8	42.2	42.2
Operating ROIC (%)	15.8	16.1	17.5	18.6	19.9
	12.7	13.1	14.4	15.3	16.5
ROE (%)	14.5	15.5	16.8	17.3	17.8
ROA (%) * Pre exceptional, pre goodwill and fully diluted	10.1	10.7	11.8	12.2	12.7
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	20268
Thai patient revenue	67,286	70,866	76,733	82,741	89,217
International patient revenue	21,248	26,211	30,142	32,855	35,812
Other revenue	4,433	5,034	5,436	5,708	5,993

Sources: Bangkok Dusit Medical Services; FSSIA estimates

# **FINANSIA**

# **Financial Statements**

Bangkok Dusit Medical Services

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
ecurring net profit	12,606	14,375	16,413	17,928	19,652
epreciation	5,950	5,848	6,243	6,766	7,27
ssociates & minorities	-	-	-	-	
ther non-cash items	1,275	1,203	590	667	75
Change in working capital	720	161	1,291	1,142	1,23
Cash flow from operations	20,551	21,588	24,537	26,503	28,91
Capex - maintenance	(14,953)	(11,612)	(11,231)	(9,704)	(10,482
Capex - new investment	-	-	-	-	
let acquisitions & disposals	(386)	(290)	0	0	
Other investments (net)	-	-	-	-	(40.40)
Cash flow from investing	(15,340)	(11,902)	(11,231)	(9,704)	(10,482
Dividends paid	(7,943)	(10,343)	(11,124)	(11,489)	(12,550
Equity finance	0	0	0	0	
Debt finance	4,764 299	(5,460)	(500) 0	(500) 0	(500
Other financing cash flows	(2,880)	612 ( <b>15,190)</b>	(11,624)	(11,989)	
cash flow from financing Ion-recurring cash flows	(2,000)	(15,150)	(11,024)	(11,909)	(13,050
Other adjustments	- 0	- 0	- 0	- 0	
let other adjustments	0	0	0	0	
lovement in cash	2,330	(5,505)	1,681	4,810	5,37
ree cash flow to firm (FCFF)	5,842.84	10,232.29	13,806.49	17,285.67	18,901.1
ree cash flow to equity (FCFE)	10,273.66	4,838.23	12,805.74	16,298.92	17,928.4
	10,270.00	.,000.20	,000.74		,520.4
Per share (THB)					
CFF per share	0.37	0.64	0.87	1.09	1.1
CFE per share	0.65	0.30	0.81	1.03	1.1
tecurring cash flow per share	1.25	1.35	1.46	1.60	1.7
alance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026
	155,412		176,546		196,73
angible fixed assets (gross)		165,315		186,250	
ess: Accumulated depreciation angible fixed assets (net)	(63,503) <b>91,909</b>	(67,642) <b>97,673</b>	(73,884) <b>102,662</b>	(80,650) <b>105,600</b>	(87,921 108 81
angible fixed assets (net)	19,160	97,673 19,376	19,376	19,376	108,81 19,37
ong-term financial assets	13,100	13,370	19,370	13,370	19,37
nvest. in associates & subsidiaries	- 1,986	- 2,276	- 2,276	- 2,276	2,27
Cash & equivalents	14,972	9,467	11,148	15,958	2,27
/C receivable	10,484	11,558	11,558	11,558	11,55
nventories	2,211	2,420	2,652	2,859	3,08
Other current assets	132	101	111	120	13
Current assets	27,799	23,545	25,469	30,495	36,10
Dther assets	689	726	726	726	72
otal assets	141,543	143,596	150,508	158,472	167,29
Common equity	89,879	95,242	100,531	106,970	114,07
/inorities etc.	3,834	3,630	4,220	4,887	5,64
otal shareholders' equity	93,713	98,872	104,752	111,857	119,71
ong term debt	23,062	18,134	17,634	17,134	16,63
Other long-term liabilities	10,032	10,973	10,973	10,973	10,97
ong-term liabilities	33,094	29,107	28,607	28,107	27,60
VC payable	6,176	6,901	7,564	8,155	8,79
Short term debt	532	0	0	0	0,10
Other current liabilities	8,028	8,715	9,586	10,353	11,18
Current liabilities	14,736	15,616	17,149	18,508	19,97
otal liabilities and shareholders' equity	141,543	143,596	150,508	158,472	167,29
let working capital	(1,377)	(1,538)	(2,828)	(3,971)	(5,205
nvested capital	112,367	118,513	122,211	124,006	125,98
Includes convertibles and preferred stock which is be	ing treated as debt				
er share (THB)					
	5 66	5.00	6.33	6 72	74
ook value per share angible book value per share	5.66 4.45	5.99 4.77	6.33 5.11	6.73 5.51	7.1 5.9
inancial strength	4.40	7.//	0.11	0.01	0.9
-	0.0	0.0	<u> </u>		10.0
let debt/equity (%)	9.2	8.8	6.2	1.1	(3.9
let debt/total assets (%)	6.1	6.0	4.3	0.7	(2.8
urrent ratio (x)	1.9	1.5	1.5	1.6	1.
F interest cover (x)	19.6	14.0	33.7	46.6	63.
aluation	2022	2023	2024E	2025E	2026
Recurring P/E (x) *	35.0	30.7	26.9	24.6	22.
Recurring P/E @ target price (x) *	44.1	38.7	33.9	31.0	28.
Reported P/E (x)	35.0	30.7	26.9	24.6	22.
lividend yield (%)	1.8	2.3	2.5	2.6	2.
rice/book (x)	4.9	4.6	4.4	4.1	3.
Price/tangible book (x)	6.2	5.8	5.4	5.0	4.
V/EBITDA (x) **	19.8	18.3	16.3	14.8	13.
V/EBITDA @ target price (x) **	24.8	23.0	20.5	18.6	17.
V/invested capital (x)	4.0	3.8	3.7	3.6	3.

Sources: Bangkok Dusit Medical Services; FSSIA estimates



# Bangkok Dusit Medical Serv (BDMS TB)

**FSSIA ESG rating** 

 $\star \star \star \star$ 

74.00 /100

### Exhibit 2: FSSIA ESG score implication

Score Rating Implication >79-100 Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to  $\star \star \star \star \star$ higher profitability >59-79 A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.  $\star \star \star \star$ >39-59 Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day  $\star \star \star$ operations, in which targets and achievements are evaluated annually. >19-39 Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to  $\star \star$ provide intensive disclosure. Most targets are conventional and achievable. 1-19 The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability  $\star$ management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC

Sources: FSSIA estimates

#### Exhibit 3: ESG – peer comparison

	FSSIA		Domestic ratings						Global ratings					Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

## Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	—	—	3	4	9	35	9	34
GHG scope 2 location-based	_	—	91	92	98	94	96	209
GHG Scope 3	_	—	—	—	—	—	_	_
Carbon per unit of production	_	—	—	—	—	—	_	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	—	_	_	_	_	_	_	5
Electricity used	—	_	143	145	152	147	192	417
Fuel used - natural gas	—	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation



# Exhibit 5: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No							
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Hazardous waste	—	—	1	2	2	2	3	5
Total waste	_	—	6	7	7	5	9	13
Waste recycled	_	—	0	1	1	0	1	2
Waste sent to landfills	_	—	_	_	—	_	3	5
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Water policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Water consumption	-	-	354	358	388	332	472	754
Social								
Human rights policy	Yes							
Policy against child labor	No	No	No	No	No	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes							
Gender pay gap breakout	No							
Pct women in workforce	—	—	82	82	82	82	83	83
Pct disabled in workforce	—	—	_	—	—	—	-	-
Business ethics policy	Yes							
Anti-bribery ethics policy	Yes							
Health and safety policy	Yes							
Lost time incident rate - employees	—	-	0	0	0	0	0	1
Total recordable incident rate - employees	—	-	2	2	2	1	1	1
Training policy	Yes							
Fair remuneration policy	No							
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,495
Employee turnover pct	—	—	18	19	19	17	16	20
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,320
Social supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Governance								
Board size	15	14	13	14	14	16	18	17
No. of independent directors (ID)	7	6	6	6	6	7	7	7
No. of women on board	2	1	1	1	1	2	2	2
No. of non-executive directors on board	9	7	6	8	9	9	9	9
Company conducts board evaluations	Yes							
No. of board meetings for the year	13	13	14	12	13	12	12	12
Board meeting attendance pct	95	94	98	97	98	98	97	100
Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No							
Age of the youngest director	45	42	43	44	45	46	47	48
Age of the oldest director	83	84	85	86	87	88	89	90
No. of executives / company managers	4	5	5	5	6	7	5	5
No. of female executives	1	1	1	2	1	2	2	2
Executive share ownership guidelines	No							
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	10	9	10	7	10	6	6	6
Audit meeting attendance %	100	100	100	100	97	100	100	100
Size of compensation committee	4	4	4	4	4	3	3	3
No. of ID on compensation committee	3	3	3	2	2	2	2	2
No. of compensation committee meetings	3	1	4	4	3	4	4	3
Compensation meeting attendance %	100	100	100	100	100	100	100	100
Size of nomination committee	4	4	4	4	4	3	3	3
No. of nomination committee meetings	3	1	4	4	3	4	4	3
Nomination meeting attendance %	100	100	100	100	100	100	100	100
Sustainability governance								
Verification type	No							

Sources: Bloomberg; FSSIA's compilation

## **Disclaimer for ESG scoring**

ESG score	Methodolog	<u>ay</u>			Rating					
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process bas from the anr Only the top inclusion.	ed on the com nual S&P Glob -ranked comp	transparent, rules-based panies' Total Sustainabi al Corporate Sustainabil anies within each indust	ility Scores resulting lity Assessment (CSA). ry are selected for	Sustainability A ESG Score of le scoring compar selected from th	ssessment (C ess than 45% ny are disquali ne Eligible Uni		mpanies with al ESG Score lents of the D	an S&P Globa of the highest JSI indices are	
Sustainability Investment List ( <u>THSI</u> ) by The Stock Exchange of Thailand ( <u>SET</u> )	managing bu Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of th shareholders come key disque pendent direct related to CG,	ility in Environmental and ansparency in Governar preemptive criteria, with he board members and e , and combined holding ualifying criteria include: tors and free float violati , social & environmental arrnings in red for > 3 ye	nce, updated annually. In two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below ion; 3) executives' impacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight a maximum, and no cap for number of stocks.					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by Thailand (SE	the Thai IOD,	h in sustainable develop with support from the St ts are from the perspecti s.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatm	8 for Good (70 or scores belov nent of shareh 5%); 4) disclo	ories: 5 for Excel -79), 2 for Fair (6 w 50. Weightings iolders (weight 2 sure & transpare	0-69), 1 for P include: 1) th 5% combined	ass (60-69), e rights; 2) an ); 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent a out of five th criteria cove date (45%), <i>circulation of s</i> <i>exercised. The</i> <i>and verifiability</i>	e incorporated and sufficiently e CG compon r AGM proced and after the r sufficient informa e second assess y; and 3) openne	which shareholders' right d into business operation y disclosed. All form imp rents to be evaluated an iures before the meeting meeting (10%). (The first a tion for voting; and 2) facilita es 1) the ease of attending r ses for Q&A. The third involv es, resolutions and voting re	as and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be neetings; 2) transparency es the meeting minutes that	be					
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies d Declaration of Certification, ir managers and	nt of key contr e Certification i eciding to becon Intent to kick off including risk ass	Checklist include corrupt ols, and the monitoring a is good for three years. an 18-month deadline to su essment, in place of policy a ablishment of whistleblowing II stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for and control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
<u>Morningstar</u> Sustainalytics	based on an risk is unma regulatory filing	assessment on aged. Sources gs, news and other	sk rating provides an ove of how much of a compa s to be reviewed include corp her media, NGO reports/web	ny's exposure to ESG porate publications and psites, multi-sector			score is the sum higher ESG risk Medium		d risk. The Severe	
		uality & peer rev	k, ESG controversies, issuer iews.	Teedback on draft ESG	0-10	10-20	20-30	30-40	40+	
<u>ESG Book</u>	positioned to the principle helps explain over-weighti	o outperform o of financial m n future risk-ad	sustainable companies ti wer the long term. The m ateriality including inform djusted performance. Ma th higher materiality and vrly basis.	nethodology considers nation that significantly ateriality is applied by	scores using m	ateriality-base	ated as a weight d weights. The s dicating better p	core is scaled		
<u>MSCI</u>				anagement of financially their exposure to ESG ri					ethodology to	
	AAA	8.571-10.00	Leader:	leading its industry in m	anaging the most si	gnificant ESG ris	sks and opportunitie	s		
	AA	7.143-8.570				-				
	A BBB	5.714-7.142 4.286-5.713		a mixed or unexception	al track record of ma	anaging the mos	t significant ESG ris	ks and opportu	nities relative to	
	BB	2.857-4.285	-	industry peers						
	в	1.429-2.856		lagging its industry have	ad on its high over	ure and failure to	manage significan	t ESC riaka		
	CCC 0.000-1.428 Laggard: lagging its industry based on its high exposure and failure to manage significant ESG risks									
<u>Moody's ESG</u> solutions	believes that	t a company ir		take into account ESG o nto its business model an medium to long term.						
<u>Refinitiv ESG</u> rating	based on pu	blicly available	e and auditable data. Th	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performan	ce and insufficie	nt degree of ti		
<u>S&amp;P Global</u>				asuring a company's perf ssification. The score ran			of ESG risks, op	portunities, an	d impacts	
	ESG Score		Bloomberg score evalu	ating the company's agg						
Bloomberg			score is based on Bloo of Pillar Scores, where	mberg's view of ESG fina the weights are determir						

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

# **FINANSIA**

# **GENERAL DISCLAIMER**

### ANALYST(S) CERTIFICATION


#### Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

#### History of change in investment rating and/or target price



Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 27.75	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Source: FSSIA estimates

#### Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 13-Aug-2024 unless otherwise stated.



# **RECOMMENDATION STRUCTURE**

#### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

#### **Industry Recommendations**

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

